PATENT CLAIM ANALYSIS

Application Number: 16406695
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-11
Patent Classification: ["435", "006100"]

Abstract:
The present disclosure provides methods of treating a patient with infliximab or alternative therapies to reduce the risk of developing, and/or severity of, an adverse drug reaction such as drug-induced liver injury. The methods include identifying patients at risk for developing DILI by determining the presence or absence of one or more HLA alleles in the patients.

Claim (Index 4):
The method of  claim 1 , wherein the subject is identified as not having the genetic variation based on the results of a genetic assay, wherein the genetic assay comprises obtaining a PCR-amplified genomic DNA sample of the biological sample from the subject, contacting under hybridizing conditions the genomic DNA with an oligonucleotide that specifically hybridizes to HLA-B*39:01, and detecting the presence or absence of HLA-B*39:01 in the sample.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 100.0
- Lexical Diversity: 1.29787
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16406698', '16406700', '14382105', '14652298', '15039919']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5969682003448976
- 35 USC 102 Novelty (BERT): 0.6263279813040414
- Combined Prediction Score: 0.599904178440812
- Mean Citation Score: 401.918542
- Max Citation Score: 595.2871
- Similarity Product: 516.7153593312919

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test